Brief: C4 Therapeutics And Betta Pharmaceuticals Announce Exclusive Licensing Agreement

C4 Therapeutics

30/05/2023 12:48

May 30 (Reuters) - C4 Therapeutics Inc  CCCC.O :
    * C4 THERAPEUTICS AND BETTA PHARMACEUTICALS ANNOUNCE
EXCLUSIVE
LICENSING AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION IN
GREATER CHINA OF CFT8919, AN ORALLY BIOAVAILABLE BIDAC™ DEGRADER
OF EGFR L858R FOR NSCLC
    * C4 THERAPEUTICS INC - C4 THERAPEUTICS TO RECEIVE A $10
MILLION
UPFRONT PAYMENT, A $25 MILLION EQUITY INVESTMENT
    * C4 THERAPEUTICS INC -  CO ELIGIBLE TO RECEIVE UP TO $357
MILLION
FOR DEVELOPMENT AND COMMERCIAL MILESTONES PLUS ROYALTIES ON NET
SALES IN GREATER CHINA
    * C4 THERAPEUTICS INC -  BETTA PHARMACEUTICALS ELIGIBLE TO
RECEIVE
ROYALTIES ON NET SALES OUTSIDE OF GREATER CHINA
    * C4 THERAPEUTICS INC - C4T RETAINS RIGHT TO DEVELOP AND
COMMERCIALIZE CFT8919 IN ALL TERRITORIES OUTSIDE OF GREATER
CHINA

Source text for Eikon:  ID:nGNX7NY8Rg 
Further company coverage:  CCCC.O 

 ((Reuters.Briefs@thomsonreuters.com;))